Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma After Radical Surgery With Donafenib in Combination With Envafolimab: a Prospective, Multicentre, Single-arm Phase II Clinical Study
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Donafenib (Primary) ; Envafolimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Jul 2024 New trial record